Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Health & Fitness
Sports
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/e8/c7/b5/e8c7b528-17b1-e0a9-427d-622bcbb740e8/mza_3250078780769455117.jpg/600x600bb.jpg
CReATe Podcast
CReATe Consortium
79 episodes
2 weeks ago
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Show more...
Health & Fitness
RSS
All content for CReATe Podcast is the property of CReATe Consortium and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Show more...
Health & Fitness
https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg
CReATe Author Series Ep. 15 - Drs. Terry Heiman-Patterson and Michael Benatar on Clinical Guidance for ALS/FTD at-risk carriers
CReATe Podcast
32 minutes
5 months ago
CReATe Author Series Ep. 15 - Drs. Terry Heiman-Patterson and Michael Benatar on Clinical Guidance for ALS/FTD at-risk carriers
Dr. Terry Heiman-Patterson is a neurologist and professor at Temple University and the director of the Center for Neurodegenerative Disorders and the MDA/ALS Center of Hope.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  In this podcast they will be discussing their recent publication “Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD”.
CReATe Podcast
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.